Although randomized clinical study data to guide the optimal timing for ART initiation are lacking [47], the WHO recommends initiating ART for all patients with HIV and drug-resistant tuberculosis requiring second-line anti-tuberculosis drugs, irrespective of CD4 cell count, as early as possible (within the first 8 weeks) following the initiation of tuberculosis treatment [50]. This evidence concerns the gene CD4 and tuberculosis.